In vivo reprogramming: A new approach for tissue repair in chronic diseases

Authors

  • Saman Esmaeilnejad PhD Candidate, Department of Physiology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Esmaeil Rahimi PhD Candidate, Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran
  • Mohammad Sajad Emami-Aleagha PhD Candidate, Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Iman Sadeghi PhD Candidate, Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran

DOI:

https://doi.org/10.22122/cdj.v5i2.237

Keywords:

Cellular Reprogramming, Chronic Disease, Guided Tissue Regeneration, Cellular Reprogramming Techniques

Abstract

Medical researchers and biologists have long been fascinated by the possibility of changing the identity of cells, a phenomenon known as cellular plasticity. Now, we know that differentiated cells can be experimentally coaxed to become pluripotent (cellular reprogramming). Recent studies have demonstrated that changes in cell identity are not limited to the laboratory, but also the tissue cells in live organisms are subjected to this process, too (endogenous cellular reprograming). Nowadays “reprogramming technology” has created new opportunities in understanding human chronic diseases, drug discovery, and regenerative medicine. This technology have enabled the generation of various specific cell types including cardiomyocytes, pancreatic beta cell, and neurons, from patient’s cells such as skin fibroblasts. Reprogramming technology provides a novel cell source for autologous cell transplantation. But, cell transplantation faces several difficult hurdles such as cell production and purification, long-term survival, and functional integration after transplantation. Recently, in vivo reprogramming, which uses endogenous cells for tissue repair, has emerged as a new approach to circumvent cell transplantation. Up till now, in vivo reprogramming has been practiced in the mouse pancreas, heart, brain, and spinal cord with various degrees of success. In this review, we summarize the progress made, therapeutic potentials, and the challenges ahead in this emerging research area.

References

Gurdon JB, Elsdale TR, Fischberg M. Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 1958; 182(4627): 64-5.

Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996; 380(6569): 64-6.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.

Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 2009; 460(7251): 49-52.

Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117(5): 663-76.

Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51(6): 987-1000.

Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463(7284): 1035-41.

Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, et al. Induction of human neuronal cells by defined transcription factors. Nature 2011; 476(7359): 220-3.

Pfisterer U, Kirkeby A, Torper O, Wood J, Nelander J, Dufour A, et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci USA 2011; 108(25): 10343-8.

Buffo A, Rite I, Tripathi P, Lepier A, Colak D, Horn AP, et al. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proc Natl Acad Sci USA 2008; 105(9): 3581-6.

Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455(7213): 627-32.

Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485(7400): 593-8.

Grande A, Sumiyoshi K, Lopez-Juarez A, Howard J, Sakthivel B, Aronow B, et al. Environmental impact on direct neuronal reprogramming in vivo in the adult brain. Nat Commun 2013; 4: 2373.

Niu W, Zang T, Zou Y, Fang S, Smith DK, Bachoo R, et al. In vivo reprogramming of astrocytes to neuroblasts in the adult brain. Nat Cell Biol 2013; 15(10): 1164-75.

Torper O, Pfisterer U, Wolf DA, Pereira M, Lau S, Jakobsson J, et al. Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci USA 2013; 110(17): 7038-43.

Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. Cell Stem Cell 2014; 14(2): 188-202.

Heinrich C, Bergami M, Gascon S, Lepier A, Vigano F, Dimou L, et al. Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex. Stem Cell Reports 2014; 3(6): 1000-14.

Su Z, Niu W, Liu ML, Zou Y, Zhang CL. In vivo conversion of astrocytes to neurons in the injured adult spinal cord. Nat Commun 2014; 5: 3338.

Graf T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 2011; 9(6): 504-16.

Fan X, Wang JZ, Lin XM, Zhang L. Stem cell transplantation for spinal cord injury: a meta-analysis of treatment effectiveness and safety. Neural Regen Res 2017; 12(5): 815-25.

Kakabadze Z, Kipshidze N, Mardaleishvili K, Chutkerashvili G, Chelishvili I, Harders A, et al. Phase 1 trial of autologous bone marrow stem cell transplantation in patients with spinal cord injury. Stem Cells Int 2016; 2016: 6768274.

Chhabra HS, Sarda K, Arora M, Sharawat R, Singh V, Nanda A, et al. Autologous bone marrow cell transplantation in acute spinal cord injury--an Indian pilot study. Spinal Cord 2016; 54(1): 57-64.

Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: A review. J Neurosci Res 2009; 87(10): 2183-200.

Segers VF, Lee RT. Protein therapeutics for cardiac regeneration after myocardial infarction. J Cardiovasc Transl Res 2010; 3(5): 469-77.

Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209(1): 10-7.

Branski LK, Gauglitz GG, Herndon DN, Jeschke MG. A review of gene and stem cell therapy in cutaneous wound healing. Burns 2009; 35(2): 171-80.

Lu P, Kadoya K, Tuszynski MH. Axonal growth and connectivity from neural stem cell grafts in models of spinal cord injury. Curr Opin Neurobiol 2014; 27: 103-9.

Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev Neurol 2010; 6(7): 363-72.

Steinbeck JA, Studer L. Moving stem cells to the clinic: potential and limitations for brain repair. Neuron 2015; 86(1): 187-206.

Gattazzo F, Urciuolo A, Bonaldo P. Extracellular matrix: a dynamic microenvironment for stem cell niche. Biochim Biophys Acta 2014; 1840(8): 2506-19.

Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, Billestrup N, et al. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell 2009; 138(3): 449-62.

Chera S, Baronnier D, Ghila L, Cigliola V, Jensen JN, Gu G, et al. Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature 2014; 514(7523): 503-7.

Baeyens L, Lemper M, Leuckx G, De Groef S, Bonfanti P, Stange G, et al. Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice. Nat Biotechnol 2014; 32(1): 76-83.

Cavelti-Weder C, Li W, Zumsteg A, Stemann-Andersen M, Zhang Y, Yamada T, et al. Hyperglycaemia attenuates in vivo reprogramming of pancreatic exocrine cells to beta cells in mice. Diabetologia 2016; 59(3): 522-32.

Juhl K, Bonner-Weir S, Sharma A. Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. Curr Opin Organ Transplant 2010; 15(1): 79-85.

Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, Chera S, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010; 464(7292): 1149-54.

Banga A, Akinci E, Greder LV, Dutton JR, Slack JM. In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. Proc Natl Acad Sci USA 2012; 109(38): 15336-41.

Ariyachet C, Tovaglieri A, Xiang G, Lu J, Shah MS, Richmond CA, et al. Reprogrammed stomach tissue as a renewable source of functional beta cells for blood glucose regulation. Cell Stem Cell 2016; 18(3): 410-21.

Li W, Nakanishi M, Zumsteg A, Shear M, Wright C, Melton DA, et al. In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypes. Elife 2014; 3: e01846.

Courtney M, Gjernes E, Druelle N, Ravaud C, Vieira A, Ben-Othman N, et al. The inactivation of Arx in pancreatic alpha-cells triggers their neogenesis and conversion into functional beta-like cells. PLoS Genet 2013; 9(10): e1003934.

Rezvani M, Espanol-Suner R, Malato Y, Dumont L, Grimm AA, Kienle E, et al. In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis. Cell Stem Cell 2016; 18(6): 809-16.

Song G, Pacher M, Balakrishnan A, Yuan Q, Tsay HC, Yang D, et al. Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis. Cell Stem Cell 2016; 18(6): 797-808.

Takeuchi JK, Bruneau BG. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature 2009; 459(7247): 708-11.

Inagawa K, Miyamoto K, Yamakawa H, Muraoka N, Sadahiro T, Umei T, et al. Induction of cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ Res 2012; 111(9): 1147-56.

Fu JD, Stone NR, Liu L, Spencer CI, Qian L, Hayashi Y, et al. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Reports 2013; 1(3): 235-47.

Ma H, Wang L, Yin C, Liu J, Qian L. In vivo cardiac reprogramming using an optimal single polycistronic construct. Cardiovasc Res 2015; 108(2): 217-9.

Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012; 485(7400): 599-604.

Nam YJ, Lubczyk C, Bhakta M, Zang T, Fernandez-Perez A, McAnally J, et al. Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. Development 2014; 141(22): 4267-78.

Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142(3): 375-86.

Protze S, Khattak S, Poulet C, Lindemann D, Tanaka EM, Ravens U. A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. J Mol Cell Cardiol 2012; 53(3): 323-32.

Sadahiro T, Yamanaka S, Ieda M. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ Res 2015; 116(8): 1378-91.

Li XH, Li Q, Jiang L, Deng C, Liu Z, Fu Y, et al. Generation of functional human cardiac progenitor cells by high-efficiency protein transduction. Stem Cells Transl Med 2015; 4(12): 1415-24.

Jayawardena TM, Finch EA, Zhang L, Zhang H, Hodgkinson CP, Pratt RE, et al. MicroRNA induced cardiac reprogramming in vivo: evidence for mature cardiac myocytes and improved cardiac function. Circ Res 2015; 116(3): 418-24.

Mathison M, Gersch RP, Nasser A, Lilo S, Korman M, Fourman M, et al. In vivo cardiac cellular reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with vascular endothelial growth factor. J Am Heart Assoc 2012; 1(6): e005652.

Kapoor N, Liang W, Marban E, Cho HC. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol 2013; 31(1): 54-62.

Chen G, Wernig M, Berninger B, Nakafuku M, Parmar M, Zhang CL. In vivo reprogramming for brain and spinal cord repair. eNeuro 2015; 2(5).

Kempermann G, Song H, Gage FH. Neurogenesis in the adult hippocampus. Cold Spring Harb Perspect Biol 2015; 7(9): a018812.

Jhaveri DJ, Tedoldi A, Hunt S, Sullivan R, Watts NR, Power JM, et al. Evidence for newly generated interneurons in the basolateral amygdala of adult mice. Mol Psychiatry 2018; 23(3): 521-32.

Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132(4): 645-60.

Li H, Chen G. In vivo reprogramming for CNS repair: Regenerating neurons from endogenous glial cells. Neuron 2016; 91(4): 728-38.

De la Rossa A, Bellone C, Golding B, Vitali I, Moss J, Toni N, et al. In vivo reprogramming of circuit connectivity in postmitotic neocortical neurons. Nat Neurosci 2013; 16(2): 193-200.

Rouaux C, Arlotta P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. Nat Cell Biol 2013; 15(2): 214-21.

Dehghan S, Asadi S, Hajikaram M, Soleimani M, Mowla SJ, Fathollahi Y, et al. Exogenous Oct4 in combination with valproic acid increased neural progenitor markers: an approach for enhancing the repair potential of the brain. Life Sci 2015; 122: 108-15.

Zhang H, Wei M, Jiang Y, Wang X, She L, Yan Z, et al. Reprogramming A375 cells to inducedresembled neuronal cells by structured overexpression of specific transcription genes. Mol Med Rep 2016; 14(4): 3134-44.

Matsui T, Akamatsu W, Nakamura M, Okano H. Regeneration of the damaged central nervous system through reprogramming technology: Basic concepts and potential application for cell replacement therapy. Exp Neurol 2014; 260: 12-8.

Niu W, Zang T, Smith DK, Vue TY, Zou Y, Bachoo R, et al. SOX2 reprograms resident astrocytes into neural progenitors in the adult brain. Stem Cell Reports 2015; 4(5): 780-94.

Liu Y, Miao Q, Yuan J, Han S, Zhang P, Li S, et al. Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo. J Neurosci 2015; 35(25): 9336-55.

Karow M, Sanchez R, Schichor C, Masserdotti G, Ortega F, Heinrich C, et al. Reprogramming of pericyte-derived cells of the adult human brain into induced neuronal cells. Cell Stem Cell 2012; 11(4): 471-6.

Faravelli I, Corti S. MicroRNA-Directed neuronal reprogramming as a therapeutic strategy for neurological diseases. Mol Neurobiol 2017. [Epub ahead of print].

Ghasemi-Kasman M, Hajikaram M, Baharvand H, Javan M. MicroRNA-mediated in vitro and in vivo direct conversion of astrocytes to neuroblasts. PLoS One 2015; 10(6): e0127878.

Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W, et al. Direct conversion of normal and Alzheimer's disease human fibroblasts into neuronal cells by small molecules. Cell Stem Cell 2015; 17(2): 204-12.

Zhou H, Dickson ME, Kim MS, Bassel-Duby R, Olson EN. Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. Proc Natl Acad Sci USA 2015; 112(38): 11864-9.

Gascon S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, et al. Identification and Successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. Cell Stem Cell 2016; 18(3): 396-409.

Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, et al. Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity. Cell Stem Cell 2016; 19(3): 341-54.

Albert K, Voutilainen MH, Domanskyi A, Airavaara M. AAV vector-mediated gene delivery to substantia nigra dopamine neurons: Implications for gene therapy and disease models. Genes (Basel) 2017; 8(2): 63.

Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. Science 2016; 353(6304): 1101-2.

Downloads

Published

2018-03-20

How to Cite

1.
Esmaeilnejad S, Rahimi E, Emami-Aleagha MS, Sadeghi I. In vivo reprogramming: A new approach for tissue repair in chronic diseases. Chron Dis J. 2018;5(2):80–89.

Issue

Section

Review Article(s)